News Sentiment

GKOS sentiment intelligence

Glaukos Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 65 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 152.72 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+3.0% over one week, +20.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Truist Adjusts Price Target on Glaukos to $180 From $160, Maintains Buy Rating

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction 3.0% Price confirming higher
Trend fit Trend active 20.4% over four weeks
Fair value 44.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 46
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 10
Investing.com 4
Quartr 3
TradingView 3
Ad Hoc News 3
simplywall.st 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 20
Analyst action 5
Regulatory and legal 1
Macro sensitivity 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 65
Investing.com Direct company coverage

Glaukos Corp stock hits 52-week high at 156.7 USD

Glaukos Corp's stock reached a 52-week high of $156.7 USD, reflecting a 58.41% increase over the past year. Despite its robust performance, the stock is considered overvalued by InvestingPro analysis, with a Fair Value estimated at $100.90, and the company remains unprofitable. R

Tone
Positive 74/100
Event
Market update
Published
15 Jul 2026 16:16
Source
Investing.com
www.marketscreener.com Direct company coverage

Glaukos Insider Sold Shares Worth $1,550,000, According to a Recent SEC Filing

An insider at Glaukos Corporation sold shares worth $1,550,000, as disclosed in a recent SEC filing. This transaction was reported on July 14, 2026. Glaukos is an ophthalmic pharmaceutical and medical technology company specializing in treatments for glaucoma, corneal disorders,

Tone
Negative 34/100
Event
Market update
Published
15 Jul 2026 05:40
Source
www.marketscreener.com
The Motley Fool Direct company coverage

Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?

Glaukos CFO Alex Thurman sold 10,000 shares of Glaukos (GKOS) stock worth $1.6 million on July 9, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite this insider sale, which represented 19% of his direct equity holdings, the article suggests it's not a bearish s

Tone
Positive 59/100
Event
Market update
Published
14 Jul 2026 22:07
Source
The Motley Fool
Investing.com South Africa Direct company coverage

Glaukos SVP & CFO Alex Thurman sells $1.55m in common stock By Investing.com

Alex R. Thurman, SVP and CFO of Glaukos Corp (NASDAQ: GKOS), executed stock option transactions on July 9, 2026, acquiring and subsequently selling 10,000 shares for a total of $1.55 million under a Rule 10b5-1 trading plan. The transactions occurred while Glaukos shares were tra

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 17:11
Source
Investing.com South Africa
Quartr Direct company coverage

Glaukos (GKOS) AGM 2026 Summary

This article provides a summary of Glaukos's (GKOS) 2026 Annual General Meeting (AGM), held on May 28, 2026, which featured a virtual format. Key agenda items included the election of two Class II directors, advisory approval of executive compensation, and ratification of the ind

Tone
Positive 72/100
Event
Regulatory and legal
Published
11 Jul 2026 04:10
Source
Quartr
Quartr Direct company coverage

Glaukos (GKOS) Stephens 26th Annual Investment Conference | NASH2024 Summary

This summary from the Stephens 26th Annual Investment Conference highlights Glaukos's focus on innovative treatments for glaucoma and corneal diseases, moving beyond traditional methods. Key products include iDose for sustained glaucoma drug delivery, which is gaining market trac

Tone
Positive 72/100
Event
Market update
Published
10 Jul 2026 23:09
Source
Quartr
TradingView Direct company coverage

Price to sales forward of Glaukos Corp – XETR:6GJ

This article provides financial information for Glaukos Corp (XETR:6GJ), specifically focusing on its forward price-to-sales ratio. It appears to be a page from a financial data platform like TradingView, showing market status and navigation options rather than a detailed analysi

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:40
Source
TradingView
Stock Titan Direct company coverage

Glaukos (GKOS) Form 144 shows 10,000-share sale, option exercise

A recent Glaukos Corporation Form 144 filing indicates an intended sale of 10,000 common stock shares by Fidelity Brokerage Services LLC on July 9, 2026, valued at $1,550,000. This sale is associated with a stock option exercise on the same date. The filing also reports previous

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 16:39
Source
Stock Titan
Market source Direct company coverage

GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?

Shares of Glaukos (GKOS) have surged over 45% since the end of May, outperforming the industry and S&P 500. This rally is primarily driven by investor confidence in its glaucoma therapy iDose TR, despite proposed Medicare restrictions, and the promising commercial launch of Epiox

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 16:09
Source
Market source
Simply Wall Street Direct company coverage

Is Glaukos’ (GKOS) Demodex Bet Quietly Reshaping Its Post-Glaucoma Ophthalmic Strategy?

Glaukos Corporation has fully enrolled 275 patients in a Phase 2 trial for GLK-321, a cream-based eyelid therapy for Demodex blepharitis, indicating a strategic expansion beyond glaucoma treatments. This move, alongside the momentum of iDose TR, suggests Glaukos is focusing on in

Tone
Positive 66/100
Event
Market update
Published
09 Jul 2026 06:41
Source
Simply Wall Street
Stock Titan Direct company coverage

Glaukos (GKOS) CFO executes pre-planned share sale and option exercise

Glaukos Corp's Chief Financial Officer, Alex R. Thurman, conducted a pre-planned transaction on July 6, 2026, exercising options for 10,000 shares at $38.68 and simultaneously selling 10,000 shares at $150.00. This activity was executed under a Rule 10b5-1 trading plan establishe

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 01:40
Source
Stock Titan
Stock Titan Direct company coverage

Glaukos (GKOS) chief development officer sells 716 shares under 10b5-1 plan

Glaukos Corp's chief development officer, Tomas Navratil, sold 716 shares of company common stock at $139.06 per share under a pre-arranged Rule 10b5-1 trading plan. This transaction, executed on July 1, 2026, represents a minor portion of his holdings, as he still directly owns

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 01:40
Source
Stock Titan
Business Wire Direct company coverage

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

Glaukos Corporation (NYSE: GKOS) announced it will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results, with rep

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 10:39
Source
Business Wire
Investing.com Direct company coverage

Glaukos Corp CFO Alex Thurman sells $1.5m in shares

Alex R. Thurman, CFO of Glaukos Corp (NASDAQ:GKOS), sold 10,000 shares for $1.5 million at $150 per share, following an option exercise for the same number of shares at $38.68. The transactions were executed

Tone
Negative 39/100
Event
Market update
Published
08 Jul 2026 09:15
Source
Investing.com
Stock Traders Daily Direct company coverage

How Glaukos Corporation (GKOS) Affects Rotational Strategy Timing

Quantitative analysis indicates strong sentiment for Glaukos Corporation (GKOS) across all time horizons, supporting an overweight bias. The article provides three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, a

Tone
Positive 74/100
Event
Analyst action
Published
07 Jul 2026 17:42
Source
Stock Traders Daily
Stock Titan Direct company coverage

Glaukos (NYSE: GKOS) files Form 144 to sell 10,000 shares

Glaukos Corp. (NYSE: GKOS) has filed a Form 144, indicating a proposed sale of 10,000 shares of common stock stemming from a Stock Option Exercise. The filing lists Fidelity Brokerage Services LLC as the broker/dealer and cites July 6, 2026, as the securities-to-be-sold date, wit

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 15:40
Source
Stock Titan
Investing.com Direct company coverage

Glaukos stock rating reiterated at Outperform by William Blair

William Blair has reiterated an Outperform rating on Glaukos Corporation (NYSE:GKOS) stock, which is trading near its 52-week high and is up 31% year-to-date despite recent losses. The reiteration comes as the company navigates a proposed local coverage determination (LCD) for it

Tone
Positive 65/100
Event
Analyst action
Published
06 Jul 2026 11:43
Source
Investing.com
StocksToTrade Direct company coverage

GKOS Jumps As Glaukos Wins Bullish Targets And Trial Milestone

Glaukos Corporation (GKOS) stock surged by 7.84% following promising trial results for its glaucoma treatment, Epioxa, which also led to increased price targets from Citi and Needham. Analysts maintain an average "Buy" rating with a mean price target of $157.50, driven by the com

Tone
Positive 82/100
Event
Analyst action
Published
04 Jul 2026 15:09
Source
StocksToTrade
Quartr Direct company coverage

Glaukos (GKOS) Proxy filing Summary

Glaukos (GKOS) has scheduled its Annual Meeting for May 28, 2026, where shareholders will vote on director elections, executive compensation, and auditor ratification. The company reported a 32% net sales growth in 2025, reaching $507M, with major product launches like iDose TR a

Tone
Positive 77/100
Event
Market update
Published
03 Jul 2026 15:39
Source
Quartr
Investing.com Direct company coverage

Glaukos stock hits 52-week high at 148.12 USD

Glaukos (GKOS) stock has reached a new 52-week high of $148.12, reflecting a 40.91% increase in value over the past year and a nearly 22% year-to-date return, despite an InvestingPro analysis suggesting it may be overvalued. The company's revenue grew 36% in Q1 2026, and it recen

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 20:12
Source
Investing.com